Allotment of Equity Shares on Preferential basis

Date: August 12, 2026 BSE Ltd., Corporate Relationship Department Phiroze Jeejheebhoy Towers Dalal Street, Mumbai – 400 001 Scrip: 526075 Sub: Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (“SEBI LODR Regulations”) – Allotment of Equity Shares on Preferential Basis Re: Company’s Board Meeting Outcome dated March 16, 2026 w.r.t. allotment of equity shares by way of preferential issue. Dear Sir/Madam, This is with reference to the Board meeting outcome dated March 16, 2026, and pursuant to the approval of the Members of the Company dated April 10, 2026 and in accordance with Regulation 30 and other applicable provisions of the SEBI LODR Regulations and in-principle approval from BSE Limited (“BSE”) dated July 30, 2026 wherein the Board of Directors of the company at its meeting held today i.e., August 12, 2026 has, inter alia, approved the following matters: 1. Allotment of 46,27,750 (Forty Six Lakhs Twenty Seven Thousand Seven Hundred Fifty) fully paid-up equity shares of the Company having face value of ₹5/- (Rupees Five Only) each at an issue price of ₹ 10/- (Rupees Ten Only) per share including premium of ₹ 5/- (Rupees Five Only) per share aggregating to ₹ 4,62,77,500/- (Rupees Four Crore Sixty Two Lakhs Seventy Seven Thousand Five Hundred Only), to existing Shareholders of Radiant Parenterals Limited (“Radiant”), being promoters and non-promoters of our company on a preferential basis, for the consideration other than cash (being swap of Purchase Shares of Radiant) towards the payment of the purchase consideration payable by the company to existing Shareholders of the Radiant, for the acquisition of 18,51,000 equity shares of face value of ₹ 10/- (Rupees Ten Only) each of Radiant, representing 100.00% of the equity share capital of Radiant. The information in connection with the allotment of securities pursuant to Regulation 30 of the SEBI LODR Regulations read with SEBI Circular No. HO/49/14/14(7)/2025-CFD-POD2/I/ 3762/2026 dated January 30, 2026, is enclosed as Annexure I. The information pursuant to Regulation 30 of SEBI LODR Regulations read with SEBI Master Circular HO/49/14/14(7)/2025-CFD-POD2/I/ 3762/2026 dated January 30, 2026, is enclosed as Annexure-II (Details of Acquisitions including Agreement to acquire) to this letter. 2. Allotment of 4,60,000 (Four Lakhs Sixty Thousand) fully paid-up equity shares of the Company having face value of ₹5/- (Rupees Five Only) each at an issue price of ₹10/- (Rupees Ten only) (including a premium of ₹5/-) per Equity Share to non-promoters of company on a preferential basis, for total consideration of ₹ 46,00,000/- (Rupees Forty-Six Lakhs Only) payable in cash; The information in connection with the allotment of securities pursuant to Regulation 30 of the SEBI LODR Regulations read with SEBI Circular No. HO/49/14/14(7)/2025-CFD-POD2/I/ 3762/2026 dated January 30, 2026, is enclosed as Annexure III CIN: L24231GJ1988PLC01145 Regd. Office: 36, Sampatrao Colony, Next to Royal Hotel, Alkapuri, Baroda -390007 Email Id: info@rekvinalaboratories.com, rekvinalimited@gmail.com Cont. No.: 0265-2362966 Accordingly, pursuant to Regulation 30 and other applicable provisions of the SEBI LODR Regulations, we wish to inform you that the Board of Directors of the Company at its meeting held today i.e., August 12, 2026 has inter alia approved the allotment of 50,87,750 (Fifty Lakh Eighty Seven Thousand Seven Hundred Fifty) Equity Shares to promoters and non-promoters on a preferential basis. The Board further noted that post-acquisition, Radiant Parenterals Limited. shall become wholly owned subsidiary of the Company. Further, the securities allotted on preferential basis shall be subject to such lock-in restriction as prescribed under Chapter V of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018. The meeting of the Board of Directors of the Company commenced at 4.00 P.M. and concluded at 4.30 P.M. Kindly take on record the same. Yours sincerely, For, Rekvina Laboratories Limited Deepak Khandelwal Company Secretary & Compliance Officer Encl.: As above. CIN: L24231GJ1988PLC01145 Regd. Office: 36, Sampatrao Colony, Next to Royal Hotel, Alkapuri, Baroda -390007 Email Id: info@rekvinalaboratories.com, rekvinalimited@gmail.com Cont. No.: 0265-2362966 Annexure I DISCLOSURE PURSUANT TO PARAGRAPH 2 OF PART A, SCHEDULE III OF THE SEBI LODR REGULATIONS READ WITH THE SEBI/HO/49/14/14(7)/2025-CFD-POD2/I/ 3762/2026 dated January 30, 2026. Preferential Issue (Disclosure post allotment of Securities): Particulars Disclosure 1. Types of securities Fully paid-up Equity Shares of the face value of ₹5/- (Rupees Five only) each proposed to be issued 2. Type of issuance Preferential issue of Equity Shares, for consideration other than cash, in accordance with the provisions of the Companies Act, 2013 and the rules made thereunder and provisions of Chapter V of Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 and other applicable laws. 3. Total number of securities 46,27,750 fully paid-up equity shares of the Company having face value of ₹ 5 each proposed to be issued or the at a price of ₹ 10 (Rupees Ten Only) per equity share including a premium of ₹5 total amount for which the (Rupees Five Only), aggregating to ₹ 4,62,77,500/- (Rupees Four Crore Sixty Two securities will be issued Lakhs Seventy Seven Thousand Five Hundred Only) on a preferential basis for consideration other than cash i.e. by way of swap of 18,51,100 equity shares of face value of ₹ 10/- (Rupees Ten Only) each of Radiant Parenterals Limited, representing 100% of the equity share capital of Radiant Parenterals Limited held collectively by Surbhit Mukesh Shah (“Seller-1”), Amit Mukesh Shah (“Seller-2”), Krima Surbhit Shah (“Seller-3”), Ami Amit Shah (“Seller-4”) and Dhruvalkumar Patel (“Seller – 5”) (who are the existing shareholders of Radiant Parenterals Limited) at a price of ₹ 25/- (Rupees Twenty Five Only) per equity share, aggregating to a total consideration of ₹ 4,62,77,500/- (Rupees Four Crore Sixty Two Lakhs Seventy Seven Thousand Five Hundred Only) for consideration by way of swap of shares. 4. Name of the investors 1. Surbhit Mukesh Shah 2. Amit Mukesh Shah 3. Dhruvalkumar Patel 4. Krima Surbhit Shah 5. Ami Amit Shah 5. Post allotment of securities Outcome of allotment: - outcome of the subscription, issue price Investor Pre Issue Shareholding Post Issue Shareholding /allotted price (in case of No. % No. % convertibles), number of Surbhit Mukesh Shah 9,17,607 15.22 24,73,857 22.26 investors Amit Mukesh Shah 8,27,883 13.73 30,09,133 27.07 Dhruvalkumar Patel Nil Nil 2,22,562 2.00 Krima Surbhit Shah Nil Nil 3,33,843 3.00 Ami Amit Shah Nil Nil 3,33,845 3.00 Total 17,45,490 28.96 63,73,240 57.34 Issue Price: Equity shares at an issue price of ₹ 10 (Rupees Ten Only) per equity share including a premium of ₹ 5 (Rupees Five Only), aggregating to ₹ 4,62,77,500/- (Rupees Four Crore Sixty Two Lakhs Seventy Seven Thousand Five Hundred Only) on a preferential basis for consideration other than cash. Number of Investors: There are 5 (Five) investors being issued Equity Shares. CIN: L24231GJ1988PLC01145 Regd. Office: 36, Sampatrao Colony, Next to Royal Hotel, Alkapuri, Baroda -390007 Email Id: info@rekvinalaboratories.com, rekvinalimited@gmail.com Cont. No.: 0265-2362966 Particulars Disclosure 6. In case of convertibles - Not Applicable Intimation on conversion of securities or on lapse of the tenure of the instrument; 7. Any cancellation or Not Applicable termination of the proposal for issuance of securities Including reasons thereof CIN: L24231GJ1988PLC01145 Regd. Office: 36, Sampatrao Colony, Next to Royal Hotel, Alkapuri, Baroda -390007 Email Id: info@rekvinalaboratories.com, rekvinalimited@gmail.com Cont. No.: 0265-2362966 Annexure II DISCLOSURE PURSUANT TO PARAGRA [Showing first 8,000 characters — download PDF for full document]